Short-term effect of evidence-based medicine heart failure therapy on glomerular filtration rate in elderly patients with chronic cardiorenal syndrome

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F09%3A00001941" target="_blank" >RIV/00216208:11120/09:00001941 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Short-term effect of evidence-based medicine heart failure therapy on glomerular filtration rate in elderly patients with chronic cardiorenal syndrome

Popis výsledku v původním jazyce

Renal failure is a frequent problem complicating chronic heart failure (CHF). Chronic kidney disease is common commorbidity in older patients with CHF. Impaired renal function is associated with morbidity and mortality in elderly patients with CHF.1,2 This risk becomes evident at an estimated glomerular filtration rate (eGFR) less than 60 mL/min per 1.73m2 (o1.0 mL/s per 1.73m2). And approximately one-third to half of patients with CHF have renal insufficiency, with an eGFR less than 60 mL/min per 1.73m2. Despite growing recognition of combined cardiac and renal dysfunction, or cardiorenal syndrome, its underlying pathophysiology is not well understood, and no consensus as to its appropriate management has been reached.3 Evidence supports use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin- receptor blockers (ARBs), beta-blockers, and aldosterone antagonists to improve survival in patients with CHF, but there is little evidence with which to weigh the risks and benefits

Název v anglickém jazyce

Short-term effect of evidence-based medicine heart failure therapy on glomerular filtration rate in elderly patients with chronic cardiorenal syndrome

Popis výsledku anglicky

Renal failure is a frequent problem complicating chronic heart failure (CHF). Chronic kidney disease is common commorbidity in older patients with CHF. Impaired renal function is associated with morbidity and mortality in elderly patients with CHF.1,2 This risk becomes evident at an estimated glomerular filtration rate (eGFR) less than 60 mL/min per 1.73m2 (o1.0 mL/s per 1.73m2). And approximately one-third to half of patients with CHF have renal insufficiency, with an eGFR less than 60 mL/min per 1.73m2. Despite growing recognition of combined cardiac and renal dysfunction, or cardiorenal syndrome, its underlying pathophysiology is not well understood, and no consensus as to its appropriate management has been reached.3 Evidence supports use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin- receptor blockers (ARBs), beta-blockers, and aldosterone antagonists to improve survival in patients with CHF, but there is little evidence with which to weigh the risks and benefits

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the American Geriatric Society

ISSN

0002-8614

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

2

Strana od-do

—

Kód UT WoS článku

000272976400052

EID výsledku v databázi Scopus

—